FAP PET/CT for Staging Patients With Breast Cancer

This study aims to evaluate the clinical utility of \[68Ga\]Ga-FAP-2268 PET/CT for disease staging and assessment in patients with high-risk primary breast cancer. By targeting fibroblast activation protein (FAP), this novel imaging approach may offer improved tumor visualization compared to conventional imaging, which may help improve treatment planning.

NCT Number	NCT07523607
Lead Sponsor	Odense University Hospital
Conditions	Breast Cancer Detection
Enrollment	65 participants
Start Date	2026-06-01
Primary Completion	2028-01 (estimated)
Study Completion	2029-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-13